Discovery Life Sciences combines the world’s largest commercial biospecimen inventory and procurement network with preeminent multi-omic service laboratories to accelerate precision medicine programs for cancer, infectious disease, and other complex conditions.
Our robust biospecimen and biomarker platform is optimized for speed and large scale capacity.
We routinely manage hundreds of global studies and expertly test thousands of biospecimens simultaneously as a single supplier –
Allowing for a single chain of custody and eliminating time consuming and inefficient transfers of biospecimens or data between different vendors. Leading biopharma, diagnostic and academic institutions trust us to quickly deliver high-quality biospecimens and associated clinical data as well as reliable, reproducible biomarker data, so they can outpace their competition and push the leading edge of innovation.
* Discovery’s clients report more than 50% faster timelines when compared to sourcing our services from separate vendors
We accomplish this with a biobank of over 10 million biospecimens and hundreds of clinical sites (Discovery Partners®) that allow researchers to build bespoke study cohorts and seamlessly interrogate them using our CLIA certified, GLP-compliant service laboratories, including our world-renowned genomic sequencing and bioinformatics laboratory, HudsonAlpha Discovery, our expert tissue biomarker services laboratory that built the pembrolizumab companion diagnostic prototype, our laboratory providing extensive cell culture and flow cytometry services and GMP-compliant leukapheresis products for cell therapy development and manufacturing.